Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Determines A “Class Effect” Is In Play For All NSAIDs

This article was originally published in The Tan Sheet

Executive Summary

An FDA decision to request revised safety labeling changes to OTC NSAIDs enables manufacturers to continue positioning the drugs as safer alternatives to their prescription counterparts, which will carry "black box" warnings going forward

Related Content

Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
High-Dose Ibuprofen, COX-2s Show Similar Vascular Event Risk – Study
COX-2 Heart Risk Mechanism Suggested By Mouse Study Results
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Wyeth Says NSAID Risk Label May Confuse Consumers
Pfizer CEO McKinnell Says OTCs Still Provide Value
Pfizer Sees Celebrex Script Growth In Days Following Bextra Withdrawal
Ads For Aleve, Tylenol Arthritis Lines Launch In Wake Of NSAID Warning 
Naproxen May Be “Exception” To NSAID Rule, But Data Is Lacking – FDA
Pfizer Consumer Business Not Critical During “Transition” Year





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts